Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized phase III study to compare conventional chemotherapy (CHOEP-14) + rituximab vs high-dose chemotherapy followed by autologous stem cell transplantation (Mega-CHOEP-21) + rituximab in younger patients with aggressive NHL

X
Trial Profile

A randomized phase III study to compare conventional chemotherapy (CHOEP-14) + rituximab vs high-dose chemotherapy followed by autologous stem cell transplantation (Mega-CHOEP-21) + rituximab in younger patients with aggressive NHL

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Vincristine
  • Indications B-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms R-MegaCHOEP
  • Most Recent Events

    • 01 May 2024 Results investigating the use of high-dose chemotherapy and rituximab with subsequent autologous stem cell transplantations compared to conventional immunochemotherapy (R-CHOEP) for high-risk patients up to 60 years, published in the Leukemia
    • 13 Mar 2020 Results comparing International prognostic indices in diffuse large B-cell lymphoma using different trials published in the Blood
    • 06 Nov 2019 Results of 10-year follow-up of this study, were released in the 61st Annual Meeting and Exposition of the American Society of Hematology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top